← Back to Screener
Elutia Inc. Class A Common Stock (ELUT)
Price$1.12
Favorite Metrics
Price vs S&P 500 (26W)20.47%
Price vs S&P 500 (4W)-4.95%
Market Capitalization$49.20M
P/E Ratio (Annual)0.92x
All Metrics
Book Value / Share (Quarterly)$0.65
P/TBV (Annual)1.13x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-37.01%
Cash Flow / Share (Quarterly)$-1.09
Price vs S&P 500 (YTD)61.81%
Gross Margin (TTM)49.14%
Net Profit Margin (TTM)282.63%
EPS (TTM)$1.23
10-Day Avg Trading Volume0.06M
EPS Excl Extra (TTM)$1.23
Revenue Growth (5Y)-22.04%
EPS (Annual)$1.29
ROI (Annual)192.90%
Gross Margin (Annual)53.66%
Net Profit Margin (5Y Avg)-11.71%
Cash / Share (Quarterly)$0.85
P/E Basic Excl Extra (TTM)0.92x
Revenue Growth QoQ (YoY)-40.18%
P/E Normalized (Annual)0.92x
ROA (Last FY)85.61%
Revenue Growth TTM (YoY)-22.51%
EBITD / Share (TTM)$-0.71
Operating Margin (TTM)-156.54%
Cash Flow / Share (Annual)$-1.09
P/B Ratio1.78x
P/B Ratio (Quarterly)1.07x
Net Income / Employee (Annual)$1
EV / Revenue (TTM)0.68x
Net Interest Coverage (TTM)-1.87x
ROA (TTM)129.48%
EPS Incl Extra (Annual)$1.29
Current Ratio (Annual)2.22x
Quick Ratio (Quarterly)2.03x
3-Month Avg Trading Volume0.28M
52-Week Price Return-45.24%
P/E Incl Extra (TTM)0.92x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.61
P/S Ratio (Annual)4.00x
Asset Turnover (Annual)0.20x
52-Week High$2.64
Operating Margin (5Y Avg)-115.31%
EPS Excl Extra (Annual)$1.29
CapEx CAGR (5Y)24.00%
26-Week Price Return29.21%
Quick Ratio (Annual)2.03x
13-Week Price Return36.26%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.22x
Enterprise Value$12.853
Revenue / Share Growth (5Y)-41.06%
Asset Turnover (TTM)0.46x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)1.75x
Pretax Margin (Annual)-129.00%
Cash / Share (Annual)$0.85
3-Month Return Std Dev70.54%
Gross Margin (5Y Avg)41.02%
Net Income / Employee (TTM)$1
ROE (Last FY)192.90%
Net Interest Coverage (Annual)-0.31x
EPS Basic Excl Extra (Annual)$1.29
Receivables Turnover (TTM)9.42x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$1.23
Receivables Turnover (Annual)6.13x
ROI (TTM)255.82%
P/S Ratio (TTM)2.61x
Pretax Margin (5Y Avg)-120.13%
Revenue / Share (Annual)$0.30
Tangible BV / Share (Annual)$0.61
Price vs S&P 500 (52W)-80.33%
P/E Ratio (TTM)0.92x
Year-to-Date Return65.95%
5-Day Price Return4.55%
EPS Normalized (Annual)$1.29
ROA (5Y Avg)-47.04%
Net Profit Margin (Annual)434.23%
Month-to-Date Return9.52%
Cash Flow / Share (TTM)$-1.72
EBITD / Share (Annual)$-0.65
Operating Margin (Annual)-218.91%
LT Debt / Equity (Annual)0.00x
P/E Excl Extra (TTM)0.92x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$1.23
P/TBV (Quarterly)1.13x
P/B Ratio (Annual)1.07x
Inventory Turnover (TTM)2.94x
Pretax Margin (TTM)-108.13%
Book Value / Share (Annual)$0.65
Price vs S&P 500 (13W)33.39%
Beta0.91x
Revenue / Share (TTM)$0.44
ROE (TTM)255.82%
52-Week Low$0.50
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.13
4.14
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
ELUTElutia Inc. Class A Common Stock | 2.61x | -22.51% | 49.14% | — | $1.12 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Elutia Inc (formerly Aziyo Biologics Inc) is a commercial-stage regenerative medicine company that develops products to improve surgical outcomes and reduce complications associated with implantable medical devices. The company operates three segments—Device Protection, Women's Health, and Cardiovascular—with Women's Health as its primary revenue driver. Its product portfolio addresses unmet clinical needs including scar tissue formation, implant rejection, capsular contraction, and device-related complications.